Healthcare Industry News: HSMN NewsFeed
News Release - April 26, 2021
Accuray Appoints Jean-Philippe Pignol, M.D., Ph.D. as Chief Medical & Technology OfficerSUNNYVALE, Calif., April 26, 2021 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Jean-Philippe Pignol, M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021. In this new role, Dr. Pignol will lead the company's scientific and clinical research activities, develop strategic collaborations with global key opinion leaders, evaluate new technologies and serve as the executive representative with important industry partners including medical societies, regulatory and legislative agencies that influence healthcare policy and reimbursement.
"We're thrilled to welcome Dr. Pignol, whose rich and unique experience base within the global radiation therapy community will help the Accuray team to achieve its vision of 'expanding the curative power of radiation therapy.' He joins the company at an important time in its growth and is a key addition to our executive leadership team," said Joshua H. Levine, president and chief executive officer.
"Dr. Pignol is a visionary with an incredible background of work with industry partners and track record of publications in the radiation therapy space," said Suzanne Winter, chief commercial officer and senior vice president, R&D at Accuray. "His clinical expertise will inform innovation, technology and new business development opportunities for the company designed to drive the personalization of radiation therapy treatments and positively change the lives of those with cancer or neurological diseases."
Dr. Pignol brings more than 26 years of experience in academia and clinical practice. For the past three years, he has served as professor and department head of the department of radiation oncology at Dalhousie University in Halifax, Canada. Previously, Dr. Pignol spent four years as professor and chair of the department of radiation oncology at Erasmus MC in Rotterdam, the Netherlands. As a board-certified radiation oncologist, he also has vast experience treating patients and has practiced throughout North America and Europe, including at the University of Toronto, Sunnybrook Cancer Center in Toronto, Canada and cancer institutes across France.
Additionally, Dr. Pignol has extensive research experience having led and participated in clinical trials designed to evaluate a wide-range of topics including the benefits of technical innovation in reducing treatment side effects for breast cancer patients, and new techniques and applications for the delivery of radiation therapy. He has authored over 125 peer-reviewed publications and was the first radiation oncologist to demonstrate the clinical benefits of intensity-modulated radiation therapy (IMRT), with a paper published in the Journal of Clinical Oncology.
"All my career has been spent in clinical care and research, developing new modalities of radiation treatments, to enable me to learn first-hand the benefits that radiation therapy can provide to patients. With the right technology, this treatment modality helps enable patients to not just live longer, but to live better and to thrive," said Jean-Philippe Pignol, M.D., Ph.D., chief medical & technology officer at Accuray. "I believe the field of Radiation Oncology is at a turning point where adaptive radiotherapy and ultra-hypofractionated regimens need optimal and dedicated solutions, where the target motion is fully controlled in real time on machines that can treat every tumor site. I have long been very impressed by Accuray and the very innovative radiation therapy delivery systems its global team has brought to market."
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the ability of the company's executives to help the company achieve its vision and inform innovation, technology and new business development opportunities for the company as well as the company's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 1, 2021, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Expands CyberKnife(R) System Versatility with Integration of RaySearch's RayStation Treatment Planning System
RayStation Latest Release, Now with Support for Accuray's CyberKnife(R) System
Geisinger becomes first in U.S. to treat cancer patients with Accuray Synchrony(R) technology on the Radixact(R) and CyberKnife(R) S7(TM) Systems to better target radiation treatments